0000886163-17-000099.txt : 20170810 0000886163-17-000099.hdr.sgml : 20170810 20170810184039 ACCESSION NUMBER: 0000886163-17-000099 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170809 FILED AS OF DATE: 20170810 DATE AS OF CHANGE: 20170810 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FOEHR MATTHEW W CENTRAL INDEX KEY: 0001237556 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 171022602 MAIL ADDRESS: STREET 1: 11119 NORTH TORREY PINES RD #200 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2017-08-09 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001237556 FOEHR MATTHEW W 3911 SORRENTO VALLEY BOULEVARD, STE 110 SAN DIEGO CA 92121 0 1 0 0 President and COO Common Stock 2017-08-09 4 M 0 6100 9.97 A 101020 D Common Stock 2017-08-09 4 S 0 6100 127.5121 D 94920 D Common Stock 2017-08-09 4 M 0 850 9.97 A 95770 D Employee Stock Option (right to buy) 9.97 2017-08-09 2017-08-09 4 M 0 6100 0.0 D 2021-04-18 Common Stock 6100 43935 D Employee Stock Option (right to buy) 9.97 2017-08-09 2017-08-09 4 M 0 850 0.0 D 2021-04-18 Common Stock 850 43085 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.4774 to $127.8374, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 04/18/11. By: Charles S. Berkman For: Matthew W. Foehr 2017-08-10